MEDICINES
LAB TESTS
CONSULT DOCTORS
CANCER CARE
AYURVEDA
PARTNERSHIPS
CARE PLAN
Login
|
Signup
Offers
Order Summary
0 Item
PROCEED TO CART
Need Help?
Location IconGPS icon
QUICK BUY! Get 25% off on medicines*
Casirivimab + Imdevimab
INFORMATION ABOUT CASIRIVIMAB + IMDEVIMAB
Casirivimab + Imdevimab Uses
Casirivimab+Imdevimab is used in the treatment of Coronavirus disease (COVID-19).
How Casirivimab + Imdevimab works
Casirivimab + Imdevimab is a combination of two human immunoglobulins G-1 (IgG1), neutralizing monoclonal antibodies, that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is equally effective against the existing as well as newer emerging variants and prevents the virus from attaching to the human cell receptors.
Common side effects of Casirivimab + Imdevimab
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common
Injection site reactions (pain, swelling, redness)
CONTENT DETAILS
Written By
Dr. Swati Mishra
BDS
Reviewed By
Dr. Rajeev Sharma
MBA, MBBS
Last updated
05 Sep 2023 | 07:33 AM (UTC)
We provide you with authentic, trustworthy and revelant information
Read our editorial policy
Medicine brands for Casirivimab + Imdevimab
Ronapreve
₹112031 to ₹112031
Cipla Ltd
1 variant(s)
Casirivimab & Imdevimab
₹112031 to ₹112031
Cipla Ltd
1 variant(s)
Expert advice for Casirivimab + Imdevimab
  • Casirivimab + Imdevimab, a monoclonal antibody cocktail therapy, is used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents aged 12 years and older, who weigh at least 40 kg.
  • The use of monoclonal antibodies is not indicated in severe hospitalized cases of COVID-19 or in those who require oxygen therapy.
  • Even after the treatment, you should continue to practice (COVID)-appropriate behavior such as wearing a mask, social distancing, avoiding sharing personal items, and frequent handwashing.
  • Before taking this antibody cocktail therapy, inform your doctor if you have any underlying medical conditions like diabetes, heart disease, high blood pressure, kidney disease, asthma, etc.
  • Patients should be monitored during treatment and at least one hour after the completion of the infusion.
  • Severe allergic reactions might happen during and after the use of monoclonal antibodies. Inform your doctor or nurse immediately if you experience shortness of breath, rapid or slow heart rate, chest pain, swelling of the face or lips, sweating.
Frequently asked questions for Casirivimab + Imdevimab
Monoclonal antibodies are specific proteins that mimic the immune system’s ability to fight against harmful microorganisms like viruses. Casirivimab and Imdevimab, the monoclonal antibodies present in Casirivimab+Imdevimab, help protect against the deadly SARS-CoV-2, the virus that causes COVID-19.
A monoclonal antibody cocktail is a combination of monoclonal antibodies that are available separately, but are mixed together for use as a cocktail, hence the name.
SARS-CoV-2, the virus that causes COVID-19, has a spike protein on its surface that helps the virus to attach and enter the hu n body. Monoclonal antibodies are engineered to mimic this attachment with SARS-CoV-2, thereby preventing disease progression. Monoclonal antibody therapy may help in treating mild symptoms at the initial stages.
Monoclonal antibody therapy for COVID-19 should be taken after the early diagnosis of COVID-19 in patients aged 12 years or older with a bodyweight of at least 40 kg. It may also be taken by people who are at a high risk of developing a severe infection, such as those aged 60 years or above, who have comorbidities such as diabetes or hypertension, and those who are immunocompromised.
Monoclonal antibodies for COVID-19 should not be taken by those who are hospitalized or need oxygen therapy. Additionally, it should not be taken by those under oxygen treatment due to pre-existing comorbidities that may not be associated with COVID-19. Those who are allergic to any of the two medicines in Casirivimab+Imdevimab or any of the other ingredients of the kit should also avoid taking this combination of monoclonal antibodies.
People aged above 60 years, who are obese, have comorbid conditions related to lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients) are at high risk of developing severe COVID-19.
Casirivimab+Imdevimab is given as an injection into a vein (intravenously) or below the skin (subcutaneously), by a healthcare professional, in a hospital to treat mild to moderate symptoms of COVID-19. It should never be injected into a muscle (intramuscularly).
Yes, Casirivimab+Imdevimab can be taken by patients with high blood pressure or diabetes, if prescribed. As per the available data, the benefits of using monoclonal antibody therapy are more significant than the potential risks.